[Effect of a new benzodiazepine derivative on experimental malignant melanomas].

Abstract

It was found, that (+)cis-3,4-dimethoxy-10,11-dimethyl-6,6aR,7,8,13, 13aS-hexahydro-[I]-benzopyrano-[4,3-b]-1,5-benzodiazepine (ZIMET 54/79) increased the life span (ILS) of C57BL/6/Jena mice suffering from transplanted B16 melanoma (ip.) by 57% (9 times ip. 250 mg/kg) and 90% (9 times ip. 500 mg/kg) respectively. In B6D2F1/Bln mice with transplanted B16 melanoma there was no ILS registered when a dose of 100-500 mg/kg was applied (ip. and p.o.). Using the Harding Passey melanoma (B6D2F1/Bln mice) only 59% tumour volume inhibition (500 mg/kg) without ILS was obtained. Finally ZIMET 54/79 tested on AMel 3 hamster melanoma (strain Z3) decreased the mean tumour volume by 72% (125 mg/kg).

• Authors: W Werner, K Wohlrabe, I Fichtner, W Wohlrab
• Journal: Archiv fur Geschwulstforschung (Arch Geschwulstforsch) Vol. 57 Issue 1 Pg. 17-23 ( 1987) ISSN: 0003-911X [Print] Germany
• Vernacular Title: Die Wirkung eines neuen Benzodiazepin-Derivates auf experimentelle maligne Melanome.
• PMID: 3566461 (Publication Type: Comparative Study, English Abstract, Journal Article)

Chemical References

• Antineoplastic Agents
• Benzodiazepines
• ZIMET 54-79

Topics

• Animals
• Antineoplastic Agents (therapeutic use)
• Benzodiazepines (therapeutic use)
• Cricetinae
• Dose-Response Relationship, Drug
• Drug Evaluation, Preclinical
• Female
• Male
• Melanoma (drug therapy, mortality)
• Mesocricetus
• Mice
• Mice, Inbred C57BL
• Neoplasm Transplantation
• Structure-Activity Relationship
• Time Factors